menu
    • menu
    [{"orgOrder":0,"company":"Whanin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Chlorpromazine Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | D2-like dopamine receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Whanin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Whanin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Whanin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Chlorpromazine Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | D2-like dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"Cycle Pharmaceuticals \/ Parexel"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Chlorpromazine Hydrochloride","moa":"Serotonin 2a (5-HT2a) receptor | D2-like dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Piramal Pharma Solutions \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Piramal Pharma Solutions \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for 2-Chlorophenothiazine

    Menu

    2-Chlorophenothiazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Piramal Pharma Solutions

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Piramal Pharma Solutions

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpromazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Piramal Pharma Launches Chlorpromazine Hydrochloride in US

                            Details : Chlorpromazine HCl Injection, is a 5-HT2A/D2R inhibitor, indicated to treat various disorders such as schizophrenia and other psychoses like paranoia etc.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2025

                            Lead Product(s) : Chlorpromazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Whanin Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Whanin Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpromazine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study in Healthy Subjects by Using of Chlorpromazine HCl 100mg Tablets

                            Details : Chlorpromazine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 04, 2023

                            Lead Product(s) : Chlorpromazine Hydrochloride

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cycle Pharmaceuticals

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Cycle Pharmaceuticals

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorpromazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride

                            Details : Chlorpromazine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Psychotic Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 24, 2016

                            Lead Product(s) : Chlorpromazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Parexel

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth